Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, Phase 2 study to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with moderate to severe active ulcerative colitis who have failed or are intolerant to previous treatment(s)

X
Trial Profile

Randomized, double-blind, Phase 2 study to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with moderate to severe active ulcerative colitis who have failed or are intolerant to previous treatment(s)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lusvertikimab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms CoTikiS
  • Sponsors OSE Immunotherapeutics
  • Most Recent Events

    • 19 Jan 2024 According to an OSE Immunotherapeutics media release, first results (from induction to week 10 and after 6 months of maintenance) are expected in mid-2024.
    • 19 Jan 2024 According to an OSE Immunotherapeutics media release, patient enrollment expected in Q1 2024 as the trial was redirected towards new clinical centers in countries further west in Europe concerning patients naive to biological treatments, who are much more numerous in the countries from Eastern Europe.
    • 27 Sep 2023 According to an OSE Immunotherapeutics media release, Last patient enrollment is expected for Q4 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top